230 related articles for article (PubMed ID: 21565333)
1. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.
Khodr CE; Sapru MK; Pedapati J; Han Y; West NC; Kells AP; Bankiewicz KS; Bohn MC
Brain Res; 2011 Jun; 1395():94-107. PubMed ID: 21565333
[TBL] [Abstract][Full Text] [Related]
2. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
Khodr CE; Becerra A; Han Y; Bohn MC
Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
[TBL] [Abstract][Full Text] [Related]
3. A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.
Han Y; Khodr CE; Sapru MK; Pedapati J; Bohn MC
Brain Res; 2011 Apr; 1386():15-24. PubMed ID: 21338582
[TBL] [Abstract][Full Text] [Related]
4. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.
Khodr CE; Pedapati J; Han Y; Bohn MC
Dev Neurobiol; 2012 Jun; 72(6):906-17. PubMed ID: 22021082
[TBL] [Abstract][Full Text] [Related]
5. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
6. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.
Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA
J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822
[TBL] [Abstract][Full Text] [Related]
7. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
9. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
10. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
11. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
[TBL] [Abstract][Full Text] [Related]
12. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.
Chung CY; Koprich JB; Siddiqi H; Isacson O
J Neurosci; 2009 Mar; 29(11):3365-73. PubMed ID: 19295143
[TBL] [Abstract][Full Text] [Related]
13. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
[TBL] [Abstract][Full Text] [Related]
14. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
17. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
18. Lateralized deficits after unilateral AAV-vector based overexpression of alpha-synuclein in the midbrain of rats on drug-free behavioral tests.
Gubinelli F; Cazzolla G; Negrini M; Kulacz I; Mehrdadian A; Tomasello G; Venuti C; Sarauskyte L; Jacobs F; Manfredsson FP; Davidsson M; Heuer A
Behav Brain Res; 2022 Jul; 429():113887. PubMed ID: 35405174
[TBL] [Abstract][Full Text] [Related]
19. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V
Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727
[TBL] [Abstract][Full Text] [Related]
20. Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons.
Aldrin-Kirk P; Davidsson M; Holmqvist S; Li JY; Björklund T
PLoS One; 2014; 9(7):e100869. PubMed ID: 24999658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]